Last updated: 2026-11-13 11:53:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Abbott Laboratories (ABT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $107.15, with a market capitalization of $185.75B and a P/E ratio of 39.51. Over the past 52 weeks, its price has ranged from $81.97 to $132.03. This page covers its latest market performance, valuation, price trends and company information.
$185.75B | |
$107.09 | |
$107.98 | |
$107.09 | |
$107.25 | |
373.00 | |
8.87M | |
39.51 | |
$132.03 | |
$81.97 | |
2.33% | |
12-31 |
Abbott Laboratories (ABT) is trading at $107.15 in pre-market trading as of 2026-11-13 11:46:00, down 0.09% ($0.10) from the previous close of $107.25
Pre-market trading shows how investors are pricing ABT before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Abbott Laboratories (ABT) moved from $113.60 to $107.15, representing a decline of 5.68% ($6.45).
The stock traded between $106.89 and $117.07 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 7.54 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 50.3%
ABT is currently trading at $107.15, placing it 50.3% of the way from its 52-week low of $81.97 to its 52-week high of $132.03. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 115,000 |
| CEO | Robert B. Ford |
| Founded | 1888 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Abbott Laboratories.
Dividend | |
|---|---|
| Ex-Dividend Date | Oct 15, 2026 |
| Payment Date | Nov 16, 2026 |
| Dividend Per Share | $0.63 |
Latest news related to Abbott Laboratories and ABT stock.
Boston Scientific's WATCHMAN left atrial appendage closure device continues to face declining demand despite positive clinical trial results and expansion efforts. The company expects low-single-digit sequential sales declines in Q3 2026 and assumes no market improvement in 2027, while competitors like Abbott and Edwards Lifesciences show stronger momentum in electrophysiology and structural heart segments.
Intuitive Surgical agreed to a $450 million no-fault settlement over third-party da Vinci servicing and instrument remanufacturing. While the settlement reduced Q3 GAAP EPS to $1.49, adjusted EPS rose 25% year-over-year to $3.00. Revenues grew 22% to $3 billion with procedures up 15%, demonstrating strong underlying operational momentum despite the litigation charge.
The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.
Abbott (ABT) has outperformed the S&P 500 over the past month with a +7.7% return. The company shows modest earnings growth expectations of +7.2% for the current fiscal year, with stable revenue forecasts of +12.4% growth. However, Abbott received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term, with valuation metrics indicating the stock is fairly valued relative to peers.
Abbott (ABT) announced FDA and CE Mark approvals for its UltiSynq defibrillation lead, which delivers both pacing and defibrillation therapy. The ASCEND CSP IDE trial demonstrated a 98.5% successful implantation rate, 97.5% complication-free rate, and 100% successful defibrillation in 120 tested patients. The device received FDA breakthrough designation. Competitors Medtronic and Boston Scientific also reported positive clinical results for their respective cardiac devices.
Eligible investors can buy real shares of Abbott Laboratories (ABT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Browse other US stocks in the same sector as Abbott Laboratories
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ABT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ABT shares and USD.
ABT Shares to USD
1.00 ABT shares = 107.15 USD
Calculations are estimates based on the latest available price and are for reference only.
